AFFIDEA acquired by GROUPE BRUXELLES LAMBERT
Context
The Brussels Lambert Group (GBL) has finalized the acquisition of a majority stake in Affidea, the European leader in diagnostic imaging and outpatient care, from B-FLEXION (family office), which is exiting the investment after eight years. The transaction is structured as a secondary LBO in which the current management team has reinvested a significant portion of its proceeds alongside GBL to ensure alignment of interests. This buyout marks a major step in the strategic rotation of GBL's portfolio, significantly increasing its exposure to private assets at the expense of its historic listed holdings.
AFFIDEA, which reported an EBITDA margin of LOGIN in 2021, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in 1991, Affidea is Europe's leading provider of diagnostic imaging, outpatient care, and oncology services. The group operates 320 centers in 15 countries, welcoming more than 10 million patients per year. It is recognized for its clinical excellence (more than 50% of its centers are “Eurosafe Star” certified in Europe).
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Similar deals in Healthcare & Pharma
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 06/2022 | EURAZEO | SEVETYS | FRANCE | Health Providers | Eurazeo acquired a majority stake in Sevetys from Ardian, which had previously financed the group's initial rapid expansion. The transaction included a EUR250 million equity injection from Eurazeo to fuel a new phase of aggressive growth. The investment thesis focuses on consolidating the highly fragmented French veterinary market, which is protected by specific regulatory barriers regarding clinical governance and independence. Sevetys positions itself as a sovereign French alternative to global giants like IVC Evidensia and AniCura |
| 06/2022 | TRITON PARTNERS | ESPERI CARE | FINLAND | Health Providers | Triton Partners, via its Triton Smaller Mid Cap Fund II, acquired a majority stake in Esperi Care Oy from a consortium of its former creditors, including Danske Bank, SEB, and Ilmarinen, which remain as minority shareholders. The transaction implies a majority control transfer while preserving continuity of public‑sector and employee‑management relationships, with Triton committing to a substantial capital investment to support further service development and operational improvements. The strategic rationale is rooted in Esperi Care’s established position, business model built on recurring and contract‑based care fees, strong regulatory and societal mandate |
| 02/2022 | MEINE RADIOLOGIE | ALERIS - RADIOLOGY | SWEDEN | Health Providers | The divestment of Aleris' radiology arm to Meine Radiologie Holding (backed by EQT Infrastructure) marks a significant consolidation in the Nordic diagnostic imaging market. This transaction was executed in tandem with the sale of Aleris' primary care and rehab units to Praktikertjänst, as part of a broader strategic shift. The rationale for Aleris, under Triton's ownership, is to exit non-core segments to focus exclusively on becoming a specialized healthcare provider in Scandinavia. For the acquirer, the deal provides a major entry point into the Norwegian and Swedish markets, significantly expanding its existing German-focused radiology platform |
| 01/2022 | WREN HOUSE | VOYAGE CARE | UNITED KINGDOM | Health Providers | Partners Group and Duke Street agreed to sell 100% of Voyage Care to Wren House Infrastructure Management, following approximately seven years of joint ownership since the 2014 acquisition alongside management. Key value creation initiatives delivered during the holding period include strategic management hires, continued investment in care quality, further development of specialist care disciplines, and capacity expansion through organic development and selective bolt-on acquisitions. |
| 12/2021 | RAMSAY HEALTH CARE | ELYSIUM HEALTHCARE | UNITED KINGDOM | Health Providers | Ramsay Health Care entered into a definitive agreement on December 13, 2021, to acquire 100% of the UK-based mental healthcare provider Elysium Healthcare from BC Partners to solidify its standing within the specialized British clinical landscape. This strategic acquisition was designed to bridge the gap between Ramsay’s existing acute medical hospitals and the specialized psychiatric and complex care segments where demand remains consistently high. By integrating these two distinct healthcare models, the group created a diversified clinical platform capable of managing patients through every stage of their recovery, from secure inpatient wards to community-based residential support |
| 12/2021 | VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT | VIVALTO SANTÉ | FRANCE | Health Providers | Vivalto Santé completed its third LBO, with Vivalto Partners — Daniel Caille's newly created investment management vehicle — taking control of the group. IK Partners joined as a key new minority shareholder alongside a broad consortium of reinvesting French institutional investors and the Bpifrance-Mubadala sovereign duo. The transaction is notably characterised by a strong medical and employee shareholder component, with approximately 1,000 physicians and ultimately 35% of employees targeted as co-investors |
| 11/2021 | CERBA HEALTHCARE | LABEXA | FRANCE | Health Providers | Cerba HealthCare acquired Labexa following a competitive auction process managed by Oddo BHF, beating out its main rival Biogroup. The acquisition allows Cerba to significantly strengthen its footprint in the French "Nouvelle-Aquitaine" region. The transaction followed Cerba's massive EUR1.2 billion acquisition of Lifebrain in Italy and was finalized shortly after Cerba's own LBO with EQT. The target's biologist-partners opted for an industrial exit to join a major laboratory network. |
| 10/2021 | THE CRANEMERE GROUP | OUTPATIENT IMAGING AFFILIATES | UNITED STATES | Health Providers | Cranemere Group has acquired a majority stake in Outpatient Imaging Affiliates (OIA), a leading US provider of outpatient medical imaging services. This transaction strengthens Cranemere's presence in the healthcare sector by partnering with a prominent player in the diagnostic imaging market. OIA's attractive positioning is driven by its joint venture model with hospital systems, a segment fueled by the ongoing growth in demand for care delivered outside traditional hospital settings. Outpatient imaging centers offer a cost-effective solution that enhances patient accessibility and experience while reducing healthcare costs |
| 10/2021 | ARES / BPIFRANCE | POINT VISION | FRANCE | Health Providers | Ares Management acquired a majority stake in Point Vision following a highly competitive auction process (beating Adagia, Ramsay, and Elsan). Bpifrance joined as a minority shareholder alongside Ares and the three founders who reinvested. Abenex, which entered in 2014 and held the majority since 2019, fully exited. The financing was secured through a unitranche facility provided by Tikehau Capital. The strategy focuses on expanding territorial coverage (especially in Auvergne-Rhone-Alpes and Ile-de-France) and digitizing the patient journey |
| 10/2021 | IVC EVIDENSIA | VETONE | FRANCE | Health Providers | IVC Evidensia acquired VetOne in a preemptive move to consolidate its leadership in the French market. The deal successfully bypassed a planned auction process due to a high-premium offer. The transaction provided an exit for VetOne's shareholders, including the founder, practicing veterinarians, and various private investors. The strategic rationale was to integrate VetOne's 51 clinics with IVC's existing French footprint, creating a dominant national player. The investment thesis is supported by low market consolidation in France and significant upside in ancillary services such as pet insurance, specialized medication, and premium pet food sales |
REFERENCES
Valuation range: EV 1b - 4b EUR
Revenue range: 450M - 900M EUR
EBITDA range: 100M - 200M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of AFFIDEA by GROUPE BRUXELLES LAMBERT are reserved for mynth community members. Register for free to unlock full data.
Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Target: affidea
Acquirer: groupe bruxelles lambert